For example, in the IMvigor210 anti-PD-L1 treatment cohort, patients with favorable responses exhibited significantly higher METTL1 expression compared to non- or limited-response groups, and high METTL1 expression was generally associated with a higher tumor neoantigen burden (59). This evidence concerns the gene METTL1 and neoplasm.